

ABSTRACT

5 The purinone derivative 6-amino-9-[(3R)-1-(2-
butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-
dihydro-8H-purin-8-one hydrochloride has Btk-selective
inhibitory activity and, in addition to having excellent
metabolic stability, it is a compound that exhibits a
high level of solubility and absorption with respect to
the free base and can be crystallized, hence it can serve
10 as a therapeutic agent for diseases involving B cells and
mast cells.